ramipril teva pharma 10mg tablets
teva pharma b.v. - ramipril - tablet - 10 milligram(s) - ace inhibitors, plain; ramipril
ramipril teva pharma 1.25mg tablets
teva pharma b.v. - ramipril - tablet - 1.25 milligram(s) - ace inhibitors, plain; ramipril
ramipril teva pharma 5mg tablets
teva pharma b.v. - ramipril - tablet - 5 milligram(s) - ace inhibitors, plain; ramipril
ramipril amneal 5 mg tablets
amneal pharma europe limited - ramipril - tablet - ramipril 5 mg - agents acting on the renin-angiotensin system
ramipril amneal 10mg tablets
amneal pharma europe limited - ramipril - tablet - ramipril 10 mg - agents acting on the renin-angiotensin system
ramipril amneal 1.25mg tablets
amneal pharma europe limited - ramipril - tablet - ramipril 1.25 mg - agents acting on the renin-angiotensin system
ramipril amneal 2.5mg tablets
amneal pharma europe limited - ramipril - tablet - ramipril 2.5 mg - agents acting on the renin-angiotensin system
ramipril aurobindo 1.25mg tablets
aurobindo pharma (malta) limited vault 14, level 2, valletta waterfront, floriana frn 1913, malta - ramipril - tablet - ramipril 1.25 mg - agents acting on the renin-angiotensin system
ramipril aurobindo 2.5mg tablets
aurobindo pharma (malta) limited vault 14, level 2, valletta waterfront, floriana frn 1913, malta - ramipril - tablet - ramipril 2.5 mg - agents acting on the renin-angiotensin system
ramipril an ramipril 5 mg capsule bottle
amneal pharma australia pty ltd - ramipril, quantity: 5 mg - capsule - excipient ingredients: hydrophobic colloidal silica anhydrous; pregelatinised maize starch; titanium dioxide; purified water; gelatin; sodium lauryl sulfate; brilliant scarlet 4r; patent blue v - - treatment of hypertension. data are currently not available to support the use of ramipril in renovascular hypertension. - post mi heart failure, - prevention of progressive renal failure in patients with persistent proteinuria in excess of 1 g/day. - for reducing the risk of myocardial infarction, stroke, cardiovascular death or the need for revascularisation procedures in patients 55 years of age or more who have clinical evidence of coronary artery disease, stroke, or peripheral vascular disease. - for reducing the risk of myocardial infarction, stroke, cardiovascular death or revascularisation procedures in diabetic patients 55 years or more with one or more of the following risk factors: systolic blood pressure >160mmhg or diastolic blood pressure >90mmhg (or on antihypertensive treatment); total cholesterol >5.2mmol/l; hdl cholesterol <0.9mmol/l; current smoker; known microalbuminuria; any evidence of previous vascular disease.